RT Journal Article
SR Electronic
T1 SARS-CoV-2 shifting transmission dynamics and hidden reservoirs limited the efficacy of public health interventions in Italy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.16.20248355
DO 10.1101/2020.12.16.20248355
A1 Giovanetti, Marta
A1 Cella, Eleonora
A1 Benedetti, Francesca
A1 Magalis, Brittany Rife
A1 Fonseca, Vagner
A1 Fabris, Silvia
A1 Campisi, Giovanni
A1 Ciccozzi, Alessandra
A1 Angeletti, Silvia
A1 Borsetti, Alessandra
A1 Tambone, Vittoradolfo
A1 Sagnelli, Caterina
A1 Pascarella, Stefano
A1 Riva, Alberto
A1 Ceccarelli, Giancarlo
A1 Marcello, Alessandro
A1 Azarian, Taj
A1 Wilkinson, Eduan
A1 de Oliveira, Tulio
A1 Junior Alcantara, Luiz Carlos
A1 Cauda, Roberto
A1 Caruso, Arnaldo
A1 Dean, Natalie E
A1 Browne, Cameron
A1 Lourenco, Jose
A1 Salemi, Marco
A1 Zella, Davide
A1 Ciccozzi, Massimo
YR 2020
UL http://medrxiv.org/content/early/2020/12/19/2020.12.16.20248355.abstract
AB We investigated SARS-CoV-2 transmission dynamics in Italy, one of the countries hit hardest by the pandemic, using phylodynamic analysis of viral genetic and epidemiological data. We observed the co-circulation of at least 13 different SARS-CoV-2 lineages over time, which were linked to multiple importations and characterized by large transmission clusters concomitant with a high number of infections. Subsequent implementation of a three-phase nationwide lockdown strategy greatly reduced infection numbers and hospitalizations. Yet we present evidence of sustained viral spread among sporadic clusters acting as “hidden reservoirs” during summer 2020. Mathematical modelling shows that increased mobility among residents eventually catalyzed the coalescence of such clusters, thus driving up the number of infections and initiating a new epidemic wave. Our results suggest that the efficacy of public health interventions is, ultimately, limited by the size and structure of epidemic reservoirs, which may warrant prioritization during vaccine deployment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMG is supported by Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ). MS, BDR and CB contribution was funded, in part, by the U.S. National Science Foundation RAPID grant (DMS-2028728). MS and BDR are also supported by the Stephany W. Holloway University Chair in AIDS Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study does not require an IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence and epidemiology raw data utilized, generated or analyzed during these studies are available from the authors upon request (including sequence alignment and R scripts for the phylodynamic analyses).